-
12:32:53 PM
Sign in with email
Forgot your password?
Register with email
Account Verification

AXSM Stock News

09/07/22 7:00 AM
Nasdaq : AXSM
Axsome Therapeutics Announces Publication of Post-hoc Analysis of Sunosi(R) Effect on Excessive Daytime Sleepiness in Narcolepsy or Obstructive Sleep Apnea Patients with a History of Depression in the Journal of Psychiatric Research
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced the publication of a post-hoc analysis comparing the effects
RHEA-AI
neutral
08/19/22 6:45 AM
Nasdaq : AXSM
fda approval
Axsome Therapeutics Announces FDA Approval of AUVELITY(TM), the First and Only Oral NMDA Receptor Antagonist for the Treatment of Major Depressive Disorder in Adults
AUVELITY is the first and only rapid-acting oral treatment approved with labeling of statistically significant improvement in depressive symptoms compared to placebo starting at one week 1 -4 AUVELITY uses the first new oral mechanism of action approved for major depressive disorder in over 60
RHEA-AI
very positive